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Worldwide studies have demonstrated that the human polyomavirus BK resides ubiquitously in the human population. After primary
infection, which occurs mainly during childhood, the virus seems to establish a life-long harmless infection in the host. However, impaired
immune functions may lead to reactivation of BK virus. The recent findings that associate BK virus with an increasing number of clinical
conditions, including renal, pulmonary, ophthalmologic, hepatic, neurological, and autoimmune diseases, has resuscitated the interest in this
virus as a pathogenic agent. This review focuses on polymorphisms in the genomes of non-passaged BK virus isolates from nonneoplastic
tissues, with special focus on the transcriptional control region, the regulatory proteins large T-antigen and agnoprotein, and the major capsid
protein VP1. The possible implications of genome diversity with respect to cell tropism, pathogenicity, and therapeutic strategies are
discussed.
D 2004 Elsevier Inc. All rights reserved.
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The human polyomavirus BK (BKV) was originally
isolated from the urine of a renal allograft recipient who
developed ureteric stenosis (Gardner et al., 1971). Sero-
logical surveys have shown that BKV is distributed
worldwide and has a high incidence among humans.
Primary infection occurs predominantly during childhood
and is reflected by the high prevalence of IgG antibodies
in this group of individuals. By the age of 10, antibodies
against the capsid proteins of BKV can be detected in
50% to 100% of the examined children (reviewed in
Knowles, 2001). Primary infection appears to be asymp-
tomatic, although few cases of BKV-induced mild
respiratory or urinary tract diseases, pyrexia, fatal dis-
seminated infection, and hemorrhagic cystitis have been
reported in immunosuppressed patients. After primary0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.10.021
* Corresponding author. Fax: +47 77 64 45 22.
E-mail address: ugom@fagmed.uit.no (U. Moens).infection, BKV establishes a harmless latent infection in
healthy individuals (reviewed in Do¨rries, 2001). Despite
its lack of obvious pathogenic properties in healthy
individuals, BKV immediately received major scientific
attention after its original isolation in 1971 because BKV,
together with the simultaneously discovered JC virus
(JCV), were the first human viruses that structurally and
genomically strongly resembled the oncogenic polyoma-
viruses simian virus 40 and mouse polyomavirus. In
accordance with these viruses, BKV was able to transform
cells (also human cells) in vitro and to induce tumors in
rodents. This encouraged researchers to examine a
possible role of BKV in human cancers. Although BKV
nucleic acid sequences or viral proteins have been detected
in human tumors, a role for BKV in malignancy remains
to be obtained (Corallini et al., 2001; White and Khalili,
2004). BKV has also been recognized as an important
human pathogen in non-carcinogenic diseases. Active
BKV infection has been associated with hemorrhagic
and non-hemorrhagic cystitis, uretic stenosis, tubulointer-05) 209–231
U. Moens, M. Van Ghelue / Virology 331 (2005) 209–231210stitial nephritis, asymptomatic nephritis, interstitial desqua-
mative pneumonitis, atypical retinitis, meningoencephalitis,
hepatic dysfunction, and autoimmune diseases (reviewed
in de Bruyn and Limaye, 2004; Hirsch and Steiger, 2003;
Reploeg et al., 2001). The exact mechanisms of BKV
reactivation remain elusive, but several factors may affect
the latency state of BKV and/or the outcome of BKV-
associated disease. The immune system of the host is
pivotal to control viral infections, and both inherited and
acquired immune dysfunctions increase the susceptibility
to various infectious complications. Reactivation of BKV
in individuals with inherited immune dysfunctions has
been documented in two case reports. A 6-year-old boy
with hyper-IgM syndrome, and a 5-year-old boy with
cartilage-hair hypoplasia, an autosomal recessive disease
that affects T cells and impairs humoral immune
responses, both developed severe tubulointerstitial nephr-
opathy or BKV-associated nephropathy (de Silva et al.,
1995; Rosen et al., 1983). Furthermore, frequent BKV
viruria is observed in patients with acquired immune
deficiencies (AIDS) or allograft patients treated with
immunosuppressive drugs compared to healthy controls
(reviewed in Hirsch and Steiger, 2003; Knowles, 2001).
The activation state of BKV may also be affected by
modulators like co-infections with other viruses, or
increased steroid hormone levels during pregnancy (Bend-
iksen et al., 2000; Bratt et al., 1999; Moens et al., 1994;
Smith et al., 1998; and references therein). Host cellular
determinants, such as receptors affinity for BKV and cell-
specific transcription factors that can regulate viral
expression, may explain the difference in cell tropism
between different BKV strains. Finally, the composition of
the transcription control region of BKV and mutations in
the coding regions may determine the cell permissivity of
the BKV strain. Whether polymorphisms in the genomes
of non-cell propagated BKV strains influence BKV
activity and BKV-associated diseases is the focus of this
review.Molecular biology of BKV
BKV, or polyomavirus hominis 1, belongs to the
Polyomaviridae, a family of small non-enveloped DNA
viruses. The virus has an icosahedral capsid with a diameter
of 45 nm. The capsid is built up of the viral proteins VP1,
VP2, and VP3. VP1 is the major protein and accounts for
80% of the total protein content of the virus particle. The
viral capsid consists of 360 molecules of VP1 arranged in
72 pentamers. These pentamers reside at the outer surface
of the viral capsid, while VP2 and VP3 reside in the inner
part of the particles. The genome of BKV consists of a
circular double-stranded DNA molecule of approximately
5.3 kbp that is packed with host cell histones. The genome
can be divided in three functional domains: (1) the early
region that encodes regulatory proteins, including the largeT-antigen and small t-antigen; (2) the late region that
encompasses the genetic information for the capsid proteins
VP1, VP2, VP3, and the agnoprotein; and (3) the non-
coding control region that spans the origin of replication
(O-block, 142 base-pairs) and sequences involved in
transcriptional regulation of both the early and the late
genes, referred to as the transcriptional control region
(TCR). The TCR of the proposed archetypal BK strain
WW has been arbitrarily divided into four transcription
factor binding sequence blocks, called P (68 base-pairs), Q
(39 base-pairs), R (63 base-pairs), and S (63 base-pairs) as
depicted in Fig. 1. The different BKV strains display a
marked heterogeneity in their TCR due to point mutations,
deletions, duplications, and rearrangements in this region
(reviewed in Moens and Rekvig, 2001; Moens et al., 1995).
These rearrangements, but also mutations in other parts of
the genome, may offer advantages for the virus in its host.
The possibility that mutant BKV strains with greater
propensity for replication are circulating in clinical pop-
ulations has been suggested (Stoner and Hu¨bner, 2001).
Recently, other genomic regions besides the TCR of BKV
isolates that were not propagated in cell culture have been
sequenced. This review analyzes in detail the variety of
BKV sequences obtained from different tissues and differ-
ent patients with distinct clinical conditions. We also
discuss the possible implications of BKV genome varia-
bility on the pathogenic potentials of this virus in humans.
The association of BKV with human tumors and the
diversity of BKV sequences in neoplastic tissues have been
recently reviewed elsewhere and are beyond the scope of
this review (Corallini et al., 2001; White and Khalili,
2004).BKV and polymorphism: the transcriptional control
region
In vitro cell culture studies have shown that cell passage
provokes rearrangements in the TCR of BKV. Viruses with
rearranged TCR display different oncogenic potentials in
animal models and altered replication properties in vitro
(reviewed in Moens et al., 1995). The polymerase chain
reaction technique allows the amplification of limited
amounts of BKV DNA without cell propagation. The
BKV DNA generated after PCR can then be directly
sequenced. Hence, the sequence of TCR DNA present in
clinical samples can be directly determined and mutations
induced by cell passage is avoided. An overview of the TCR
variants of BKV DNA that was directly obtained from
clinical specimens is provided in Table 1. Archetypal strains
with a linear PQRS anatomy, as well as rearranged strains
with deletions or/and duplications of complete or part of the
different blocks have been isolated from most tissues
examined (Table 2). There seems to be a selection to
preserve the P block as all described variants so far retain P
sequences, while several TCR variants lack one or several of
Fig. 1. Schematic presentation of the archetypal BKV (WW) non-coding control region using the O—P—Q—R—S nomenclature. The consensus sequence of
the P, Q, R, and S block is given. The nucleotides A/T in the P block (respectively
G/A in the R block, and
A/G in the S block) indicates that either one of these
nucleotides is preferentially found at this site. The numbers in parentheses represent the number of base pairs in each block. A broken arrow indicates the early
and late regions. Proven binding sites for transcription factors are depicted.
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variants, but two (T1R1.BK and T5R.BK clone 4; Li et al.,
2002) have also retained S block sequences, indicating the
importance of these sequences. In addition to the extensive
changes, various point mutations have been characterized in
the TCR. The point mutations in each BKV strain, as
compared to the consensus sequence given in Fig. 1, are
summarized in Table 3. Rearrangements as well as point
mutations may affect putative binding sites for host
transcription factors. This has been extensively reviewed
previously and will not be further discussed here (Moens
et al., 1995).
The conclusion whether specific BKV strains preferen-
tially reside in specific tissues is hampered for two reasons.
First, it is difficult to trace whether the detected strain is the
original one that latently infected the host tissue or whether
this strain was generated by recombination during BKV
DNA replication after reactivation of the virus. Indeed,
during latency, replication activity of the virus is absent or
low and very few genome copies are present per cell,
consequently reducing the possibility of recombination.
During reactivation of the virus, replication activity, and
therefore the number of genomes will increase. A higher
number of genome copies may lead to recombination and
creation of new TCR variants, often with more than one
origin of replication (Hara et al., 1986; Rubinstein et al.,
1991; Sugimoto et al., 1989; Watanabe and Yoshiike, 1986).
Thus, while the archetypal strain may originally latently
infect a cell, reactivation may lead to rearranged TCR
variants that replicate better than the archetypal strain. These
mutant strains may outgrow the parental virus. Secondly,
only a few studies have addressed the diversity of TCRs indifferent tissues of the same person. In one study, Stoner et
al. (2002) either PCR amplified or cloned the TCR DNA
from brain, cerebrospinal fluid (CSF), kidney, lung, and
urine from a patient with chronic lymphocyte leukemia with
a fatal case of BKV tubulointerstitial nephritis. PCR-
amplified TCR sequences from urine and lung possessed
the archetypal PQRS anatomy, whereas rearranged PQSPQS
TCR were obtained in brain and CSF samples. However,
cloning of the TCR sequences isolated from CSF, kidney,
lung and brain tissue revealed both the archetypal TCR, as
well as rearranged TCR variants (Table 1). Cloned TCR
DNA from brain and CSF from this patient exposed a
PQSPQS TCR, while PQPQS and PQPQPQRS rearrange-
ments were detected in his kidney samples. In another study,
BKV (CNS) strain with rearranged PQRSPQRS anatomy
was detected by PCR in CSF, brain, and eye tissue from an
AIDS patient, while urinary shed virus had an archetypal
PQRS TCR (Jbrgensen et al., 2003). These findings are in
agreement with Stoner et al. who by PCR observed
rearranged TCRs in the kidney, while archetypal PQRS
TCRs were detected in urine. Stoner et al., however, also
found archetypal TCR in the kidney, after cloning the BKV
DNA. Although the presence of different TCR variants in
both patients may be biological, they may also be explained
by the use of different methods to obtain the BKV
sequences. In a biological specimen containing distinct
amounts of related DNA molecules (e.g., BKV genomes),
PCR will proportionally amplify the different DNA species.
Subsequent cycle sequencing of the obtained PCR products
will generate strong signals for the abundant PCR products,
while scarcely represented DNA templates will produce
minor signals that may not exceed above the noise ratio.
Table 1
Transcriptional control region variants found among non-passaged BKV strains directly isolated from nonneoplastic tissues and body fluids from healthy individuals and patients
Strain Accession number Anatomy Point mutations Specimen References
WW and WW-like strains
A191-2 AF218448 P1–40,60–68—Q1–39—R1–63—S1–63 R5:AYG renal transplant patient Chang and Wang,
unpublishedR38:CYG
R39:TYC
R40:GYA
S22:TYG
S49—T—S50
A250-1a AF218447 P1–68—Q1–39—R1–63—S1–63 R5:AYG renal transplant patient Chang and Wang,
unpublishedR38:CYG
R39:TYA
R41:DG
S22:TYG
S49—T—S50
Azzi-U AY273186 P1–40,49–68—Q1–27—R2–63—S1–63 R17:AYT urine renal transplant
patient
Azzi et al.,
unpublishedR41:GYT
S24:GYA
S49—T—S50
Azzi–K AY272187 P1–40,49–68—Q1–25—R13–63—S1–63 R13:AYT kidney from renal
transplant patient
Azzi et al.,
unpublishedR41:GYT
S24:GYA
S49—T—S50
BMT-2,-7,-10,
-12,-13,-15-19
P1–68—Q1–39—R1–63—S1–63 P56:AYC or G urine from BMTa patients Negrini et al. (1991)
DP57
R5:AYG
R6:AYC
R38:CYG
R40:GYA
R41:CYT
BMT P1–68—Q1–39—R1–63—S1–63 Q36:CYG urine from BMT patients Priftakis et al.
(2001, 2003)Q38:CYG
R2:CYT
CAL AF317623 P1–68—Q1–39—R1–63—S1–63 P27:AYG not specified Bhattacharjee and
Chakraborty,
unpublished
P31:CYT
P56:AYG
R13:AYC
R23:AYC
R35:AYG
R43:CYA
R47:DG
CAP–h2 AY628226 P1–68—Q1–39—R1–63—S1–63 P31:CYT heart from a patient with
BKV-associated capillary
leak syndrome
Chen et al. (2004)
CAP-h5 AY628228 P1–68—Q1–39—R1–63—S1–63 P31:CYT heart from a patient with
BKV-associated capillary
leak syndrome
Chen et al. (2004)
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CAP-h8 AY628229 P1–68—Q1–39—R1–63—S1–63 P31:CYT heart from a patient with
BKV-associated capillary
leak syn ome
Chen et al. (2004)
CAP-h22 AY628227 P1–68—Q1–39—R1–63—S1–63 P31:CYT heart fro a patient with
BKV-ass ciated capillary
leak syn ome
Chen et al. (2004)
CAP-m2 AY628212 P1–68—Q1–39—R1–63—S1–63 P31:CYT striated muscle from a patient
with BK -associated
capillary eak syndrome
Chen et al. (2004)
CAP-m5 AY628232 P1–68—Q1–39—R1–63—S1–63 P31:CYT striated muscle from a patient
with BK -associated capillary
leak syn ome
Chen et al. (2004)
R29:AYG
CAP-m9 AY628233 P1–68—Q1–39—R1–63—S1–63 P31:CYT striated muscle from a patient
with BK -associated
capillary eak syndrome
Chen et al. (2004)
CAP-m13 AY628230 P1–68—Q1–39—R1–63—S1–63 P31:CYT striated muscle from a patient
with BK -associated
capillary eak syndrome
Chen et al. (2004)
CAP-m18 AY628224 P1–68—Q1–39—R1–63—S1–63 P31:CYT striated muscle from a patient
with BK -associated
capillary eak syndrome
urine SL patient
Chen et al. (2004)
cl-108 G7RBK AF374595 P1–41,49–68—Q1–39—R3–63—S1–63
P1–68—Q1–39—R1–63—S1–63
P14:TYC urinary c lls from a
FSGSb p tient
Sugimoto et al. (1989),
Li et al., unpublished
HC-u2 AY628234 P1-68—Q1–11—R22–63—S1–63 urine fro healthy control Chen et al. (2004)
HC-u5 AY628235 P1–68—Q1–39—R1–63—S1–63 urine fro healthy control Chen et al. (2004)
HC-u9 AY628236 P1–68—Q1–39—R1–63—S1–63 urine fro healthy control Chen et al. (2004)
HI-u5 AY628225 P1–68—Q1–39—R1–63—S1–63 P31:CYT urine fro HIV-2 patient Chen et al. (2004)
HI-u6 AY628237 P1–68—Q1–39—R1–63—S1–63 P31:TYC urine fro HIV-2 patient Chen et al. (2004)
R29:AYG
S18:GYA
HI-u8 AY628238 P1–39,48–68—Q1–39—R1–63—S1–63 P31:CYT urine HI -2 patient Chen et al. (2004)
R29:AYG
K8R2.BK 2+3 AF442896 +
AY442897
P1–68—Q1–39—R1–63—S1–63 P31:CYT urine fro a renal
transplan patient
Li et al. (2002)
MT-1,cl-6,-8,
-50,-87,-93
P1–68—Q1–39—R1–63—S1–63 R2:CYA urine SL patient Sugimoto et al. (1989)
R58:CYT
S22:TYG
S29:CYG
PAT-A,PAT-E S72998 P1–68—Q1–39—R1–63—S1–63 Q7:CYG urine fro AIDS patient
(PAT-A) r from acute
myeloid ukaemia patient
(PAT-E)
Scha¨tzl et al. (1994)
P1 P1–68—Q1–39—R1–63—S1–63 P31:CYT urine fro pregnant women Bhattacharjee and
Chakraborty, (2004)P55:GYT
RA AF356531 P1–68—Q1–39—R1–63—S1–4 P31:CYT sewage s mple Bofill-Mas et al. (2001)
S1,S2 P1–68—Q1–39—R1–63—S1–63 P31:CYT urine fro renal
transplan patient
Bhattacharjee and
Chakraborty, (2004)R24:AYC
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Table 1 (continued )
Strain Accession number Anatomy Point mutations Specimen References
WW and WW-like strains
S3 P1–68—Q1–39—R1–63—S1–63 P27:AYG urine from nal transplant
patient
Bhattacharjee and
Chakraborty, (2004)P31:CYT
P56:AYG
R13:AYC
R23:AYC
R35:AYG
R43:CYA
R47:DG
SA160900 AF356533 P1–68—Q1–39—R1–63—S1–4
c P31:CYT sewage sam le Bofill-Mas et al. (2001)
SA090600 AF356532 P1–68—Q1–39—R1–63—S1–4 P31:CYT sewage sam le Bofill-Mas et al. (2001)
Seq 1 P1–68—Q1–39—R1–63—S1–63 R5:AYG urine from nal transplant and
BMT patie s
Takasaka et al. (2004)
R40:GYA
S49—T—S50
Seq 2 P1–68—Q1–39—R1–63—S1–63 S49—T—S50 urine from nal
transplant p tient
Takasaka et al. (2004)
Seq 3 P1–41,50–68—Q1–39—R1–35—S55–63 R5:AYG urine from nal transplant
patient
Takasaka et al. (2004)
Seq 4 P1–68—Q1–39—R1–63—S1–63 P55:GYC urine from nal transplant and
BMT patie s
Takasaka et al. (2004)
P58:DA
R40:GYT
R41:GYT
Seq 5 P1–68—Q1–39—R1–63—S1–63 P31:CYT urine from nal transplant and
BMT patie s
Takasaka et al. (2004)
R58:CYT
Seq 7, 8 P1–68UQ1–39—R1–63—S1–63 R2:CYA urine from nal transplant and
BMT patie s
Takasaka et al. (2004)
R58:CYT
S23:AYG
S29:CYG
Seq 9 P1–68—Q1–39—R1–63—S1–63 R58:CYT urine from nal transplant
patient
Takasaka et al. (2004)
S23:AYG
S29:CYG
Seq 10 P1—41,50–68—Q1–39—R1–63—S1–63 Q34:CYT urine from nal transplant
patient
Takasaka et al. (2004)
R12:CYT
R58:CYT
S23:AYG
S29:CYG
Shi 1-6 P1–68—Q1–39—R1–63—S1–63 Q7:CYG urine HIV tients Agostini et al. (1995)
T3R2.BK AF442903 P1–31,50–68—Q1–39—R1–63—S1–63 R5:AYG urine from renal transplant
patient
Li et al. (2002)
R26:AYG
T4R3.BK cl3 AF442905 P1–38,48–68—Q1–39—R1–34—S1–63 P31:CYT urine from renal transplant
patient
Li et al. (2002)
T2M.2BK AF442894 P1–41,50–68—Q1–39—R1–63—S1–63 PBMC
d fro a renal transplant
patient
Li et al. (2002)
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TC-1 P1–68—Q1–39—R1–63—S1–63 P33:GYA urine from pregnant women and
RA patients
Tsai et al. (1997);
Chang et al. (1996a)
TC-2 P1–68—Q1–39—R1–63—S1–63 P33:GYA urine from SLE and
polymyositis patients
Tsai et al. (1997);
Chang et al. (1996a);
Chang et al. (1996b)
Q18:CYT
Q27:GYC
R2:CYG
TIM.BK AF442900 P1–68—Q1–39—R1–63—S1–63 P31:CYT PBMCd from a renal transplant
patient
Li et al. (2002)
S44:AYC
U3 AF356280 P1–68—Q1–39—R1–63—S1–4 sewage sample Bofill-Mas et al. (2001)
USA5 AF356530 P1–68—Q1–39—R1–63—S1–4 sewage sample Bofill-Mas et al. (2001)
USA2 AF356529 P1–68—Q1–39—R1–63—S1–4 sewage sample Bofill-Mas et al. (2001)
V128-1 AF218446 P1–41,50–68—Q1–39—R1–63—S1–63 R38:CYG renal transplant patient Chang and Wang,
unpublishedR40:GYA
S22:TYG
S49—T—S50
V173-1 AF218445 P1–41,50–68—Q1–39—R1–63—S1–63 R5:AYG renal transplant patient Chang and Wang,
unpublishedR38:CYG
R39:TYC
R40:GYA
S22:TYG
S49—T—S50
WW M15987 P1–68—Q1–39—R1–63—S1–63 P31:CYT urine from renal transplant
patient
Rubinstein et al. (1987)
WW P1–68—Q1–39—R1–63—S1–63 P31:CYT urine and PBMC from
AIDS patient
Jbrgensen et al. (2003)
R38:CYG
R40:GYA
S22:TYG
S49—T—S50
WW P1–68—Q1–39—R1–63US1—63 P18—T—P19 urine from pregnant women Markowitz et al. (1991)
Q8:CYG
R6:AYC
R7:AYT
S2:AYC
WW P13,50–68—Q1–39—R1–12,32–63—S1–63 brain from patient with
chronic lymphocyte
leukaemia with fatal case of
BKV tubulointerstitial nephritis
Stoner et al. (2002)
WW P1–68—Q1–39—R1–63—S1–63 kidney sample A and C from
patient with chronic
lymphocyte leukaemia with
fatal case of BKV
tubulointerstitial nephritis
Stoner et al. (2002)
WW P1–68—Q1–39—R1–63—S1–63 lung from patient with
chronic lymphocyte
leukaemia with
fatal case of BKV
tubulointerstitial nephritis
Stoner et al. (2002)
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Table 1 (continued )
Strain Accession number Anatomy Point mutations Specimen References
WW and WW-like strains
WW AF123397–
AF123428
P1–68—Q1–39—R1–63—S1–63 P24:TYC or A urine from SLE patients Sundsfjord et al. (1999)
Q39:DC
R5:AYG
R10:CYG
R38:CYG
R40:GYA
S22:TYG
S49—T—S50
WWT P1–68—Q1–39—R1–63—S1–63 urine from patient with
chronic lymphocyte
leukaemia with fatal case of
BKV tubulointerstitial nephritis
Stoner et al. (2002)
WWT1 P1–68—Q1–39—R1–63—S1–63 S29:CYT urine from AIDS and
BMT patients
Fl&gstad et al. (1991)
WWT2 P1–14,23–68—Q1–39—R1–63—S1–63 urine BMT patient Fl&gstad et al. (1991)
WWT3 P1–68—Q1–39—R1—63—S1–63 Q7:CYG urine from BMT patients Fl&gstad et al. (1991)
16a,20 P1–68—Q1–26—R1–8—S1–8
c PBMC from healthy individuals Chatterjee et al. (2000)
Rearranged strains
AO AF123403 +
AF123404
P1–67—Q1–39—R1–9—P22–68—Q1–32—
P54–68—Q1–39—R1–63—S1–63
P5:DG urine from SLE patients Sundsfjord et al. (1999)
P17:DT
P35:CYA
P62:CYA
P63:AYC
Q2—T—Q3
Q21:TYG
R3—T—R4
BK-OV1 AY573928 P1–68—Q1–6—P20–68—Q1–39—S21–63 P19:DA benign ovarian teratoma Asomani et al.,
unpublishedP24—G—P25
S22:TYG
S49—T—S50
BKV(Clin) 41 bp duplication and/or 48 bp deletion patient kidney from AIDS Smith et al. (1998)
BKV(CNS) AY236489 P1–68—Q1–26—R13–37—GTACCCG—S23–49—T—
P37–68—Q1–25—R13–37—GTACCCG—S23–63
S49—T—S50 brain, eye, and CSF from
AIDS patient
Jbrgensen et al. (2003)
BKV(Yale) P1–68—Q1–27—S20–33—P39–68—Q1–27—S20–63 brain and CSF from patient
with chronic lymphocyte
leukaemia with fatal case of
BKV tubulointestial nephritis
Stoner et al. (2002)
BKV(Yale) P1–68—Q1–33—P49–68—Q1–37—S18–63 kidney from patient with
chronic lymphocyte
leukaemia with fatal case of
BKV tubulointestial nephritis
Stoner et al. (2002)
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BKV(Yale) P1–68—Q1–39—P21–68—Q1–39—P21–68—Q1–34—R59–63—S1–63 kidney from patient with
chronic lymphocyte
leukaemia with fatal case of
BKV tubulointestial
nephritis
Stoner et al. (2002)
BKVAN-1 P1–68—Q1–39—R1–5—P51–68UQ1–36 kidney from patient
with polyomavirus-associated
nephropathy
Randhawa et al. (2003)
BKVAN-2 P1–68—Q1–28UP14–68—Q1–39—R1–63—S1–63 kidney from patient
with polyomavirus-associated
nephropathy
Randhawa et al. (2003)
BKVAN-3 P1–30,49–68—Q1–15—P49–68—Q16–39—R1–63—S1–48c kidney from patient
with polyomavirus-associated
nephropathy
Randhawa et al. (2003)
BMT-14 P1–31—P9–68—Q1–39—R1–63—S1–63 P56:AYC urine BMT patient Negrini et al. (1991)
P57:DA
R6:AYC
R40:GYT
R41:GYT
cl-51,-54,-59 P1–49—P15–68—Q1–39—R1–63—S1–63 urine from SLE patient Sugimoto et al. (1989)
cl-97 P1–39—P55–68—Q1–39UR1–63—S1–63 urine from SLE patient Sugimoto et al. (1989)
cl-7,-47,-104,-111 P1–40—O41–142—P1–68—Q1–39—R1–63—S1–63 urine from SLE patient Sugimoto et al. (1989)
cl-32 P1–68—Q1–39—R1–12—O42–142—P1–68—Q1–39—R1–63—S1–63 urine from SLE patient Sugimoto et al. (1989)
cl-44 P1–68—Q1–39—R1—31—O49–142—P1–68—Q1–39—R1–63—S1–63 urine from SLE patient Sugimoto et al. (1989)
cl-9,-11,-18,-29,
-34,-80,-120
P1–68—Q1–39—R1–31—O46–142—P1–68—Q1–39—R1–63—S1–63 urine from SLE patient Sugimoto et al. (1989)
DDP U91605 P1–68—Q1–39—S1–63 Q15:TYA PBMC from healthy and HIV+ Degener et al. (1999);
Dolei et al. (2000)
Dunlop P1–68—P1–7,25–68—P1–64—S4–63 P8:DA PBMC from immuno-
competent individuals
Do¨rries et al. (1994)
P63:AYG
NP132 P1–68—Q1–26—P20–68—Q1–39—S1–63 nasopharyngeal aspirates from
children with respiratory
diseases
Sundsfjord et al. (1994a)
NP164 (=proto-2) P1–68—P1–9,27–68—P1–68—Q1–28—AA—S7–63 urine and PBMC from
AIDS patients, naso-pharyngeal
aspirates from children with
respiratory diseases
Sundsfjord et al. (1994a),
(1994b)
PBMC-6 P1–68—Q1–31—P24–68—Q1–30—P12–68—Q1–4—S1–8c PBMC healthy individuals Chatterjee et al. (2000)
PBMC-7 P1–68—Q1–31—P17–68—Q1–18,32–39—S1–8c PBMC healthy individuals Chatterjee et al. (2000)
PBMC-9b,18,21 P1–68—Q1–26—P20–68—Q1–27—R41–63—S1–8c PBMC healthy individuals Chatterjee et al. (2000)
PBMC-9c PBMC healthy individuals Chatterjee et al. (2000)
PBMC-13 P1–68—Q1–39—R1–12—P16–68—Q1–34—S1–8c
PBMC-16b P1–68—Q1–39—S1–5—P16–68—Q1–39—S1–8c PBMC healthy individuals Chatterjee et al. (2000)
PBMC-17 P1–68—Q1–39—R1–12—P18–68UQ1—44—S1–8c PBMC healthy individuals Chatterjee et al. (2000)
PBMC-30a P1–68—Q1–26—R1–9—P37–68—Q1–25—R1–9—S1–8c PBMC healthy individuals Chatterjee et al. (2000)
PQ P1–68—Q1–39—S1–63 P43:GYA fetal brain and kidney,
placenta
Pietropaolo et al. (1998)
Q7:CYG
Q15:TYA
(continued on next page)
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Table 1 (continued )
Strain Accession number Anatomy Point mutations Specimen References
Rearranged strains
Seq 6 P1–35—P27–68—Q1–39—R1–63—S1–63 P31:CYT urine BMT patient Takasaka et al. (2004)
R58:CYT
TU M34049 P1–68—Q1–39—R1–12—T—P16–68—Q1–34—R52–63—S1–63 urine AIDS patients Sundsfjord et al. (1990);
Sundsfjord et al. (1994b)
T1R1.BK AF442901 P1–49—T—Q3–39—R1–40 P31:CYT PBMC healthy individuals
urine renal transplant patient
Chatterjee et al. (2000),
Li et al. (2002)P45:DC
P49—T—Q3
T2R.1BK AF442893 P1–68—Q1–5—P24–68—Q1–27—R30–63—S1–63 urine renal transplant patient Li et al. (2002)
T2R.2BK AF442892 P1–68—Q1–25—R47–63—Q1–25—R47–63—S1–63 P45:CYG urine renal transplant patient Li et al. (2002)
P64:TYC
T2Rbkit2 AF442895 P1–68—Q1–5UP24–68UQ1—27UR30—63US1—63 urine renal transplant Li et al. (2002)
T2RBKit21-2 AF411593 P1–68—Q1–25—R47–63—G—P46–68—
Q1–25—R47–63—S1–63
P64:TYC urinary cells from renal
transplant patient
Li et al., unpublished
T4R4.BK AF442905 P36–50—Q4–10—P21–45—TCAT—
Q3–37—TCCC—S37–63
P31:CYT urine from renal transplant
patient
Li et al. (2002)
P45:DC
P49—T—P50
T5R.BK cl 4 AF442906 P1–68—Q1–28 Q7:CYG urine from renal transplant
patient
Li et al. (2002)
TC-3 AF164514 P1–68—Q1–6—P21–68—Q1–39—R1–63—S1–63 P2:DC kidney from renal transplant
patient
Chen et al. (2001)
R2:CYA
R58:TYC
S23:AYG
S29:CYG
URO1 P1–68—Q1–26—P32–68—Q1–26—R56–63—S1–6 P4—CA—P5 nonneoplastic and neo-plastic
tissue of bladder, prostate,
kidney, and ureter
Monini et al. (1995)
WL-1 S67523 P1–40,61–68—Q1–4—O131–142—P1–40,61—68—
Q1–39—R1–49—S7–57,63
R5:AYG PBMC from immuno-
competent individuals
Do¨rries et al. (1994)
R38:CYG
R40:GYA
S18:GYA
S22:TYG
S49—T—S50
WT501 E00430 P1–68—P1–17,26–68—P1–68—Q1–39—S1–63 S10:GYA not provided Soeda and Yoshimura,
unpublishedS18:GYA
9a,30b,33 Q7:CYG healthy blood donors Chatterjee et al. (2000)
Q15:TYA
S29:CYT
a Bone marrow transplant.
b Focal segmental glomerulosclerosis.
c Downstream sequence not determined.
d Peripheral blood mononuclear cells.
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Table 2
Anatomy of the transcriptional control region variants found in different human tissues
Specimen NCCR anatomy Strain References
Bladder PQPQRS URO1 Monini et al. (1995)
Brain PQS PQ Pietropaolo et al. (1998)
PQRS BKV(Yale) Stoner et al. (2002)
PQSPQS BKV(Yale) Stoner et al. (2002)
PQRSPQRS BKV(CNS) Jbrgensen et al. (2003)
CSF PQRPQRS BKV(CNS) Jbrgensen et al. (2003)
PQSPQS, PQPQPQRS BKV(Yale) Stoner et al. (2002)
Eye PQRPQRS BKV(CNS) Jbrgensen et al. (2003)
Heart PQRS CAP-h2,-h5,-h8,-h22 Chen et al. (2004)
Kidney PQS PQ Pietropaolo et al. (1998)
PQRS Azzi-K, BKV(Yale) Azzi et al., unpublished; Stoner et al. (2002)
PQPQS BKV(Yale) Stoner et al. (2002)
PQPQRS URO1, TC-3, BKVAN Pat2 + Pat3 Monini et al., 1995; Chen et al. (2001);
Randhawa et al. (2003)
PQRPQ BKVAN Pat1 Randhawa et al. (2003)
PQPQPQRS BKV(Yale) Stoner et al. (2002)
not specified BKV (Cin) Smith et al. (1998)
Lung PQRS BKV(Yale) Stoner et al. (2002)
Muscle PQRS CAP-m2,-m5,-m9,-m13,-m15 Chen et al. (2004)
Nasopharyngeal PQPQS NP132 Sundsfjord et al. (1994b)
aspirates PPPQS NP164(=prototype) Sundsfjord et al. (1994a)
Ovarium PQPQRS URO1 Monini et al. (1995)
PBMC PQS DDP,PQ, PBMC-9a,30b,33 Degener et al. (1999); Dolei et al. (2000);
Chatterjee et al. (2000)
PPPS Dunlop, Do¨rries et al. (1994)
PQRS TIM.BK,T2M.2BK,PBMC-16a,20,WW Li et al. (2002); Chatterjee et al. (2000);
Jbrgensen et al. (2003)
PPPQS NP164 (=proto-2) Sundsfjord et al., 1994
PQPQS PBMC-7 Chatterjee et al. (2000)
PQPQRS PBMC-9b,18,21 Chatterjee et al. (2000)
PQRPQS PBMC-9c Chatterjee et al. (2000)
PQSPQS PBMC-16b Chatterjee et al. (2000)
PQRPQS PBMC-17 Chatterjee et al. (2000)
PQPQPQS PBMC-6 Chatterjee et al. (2000)
PQRSPQRS PBMC-13 Chatterjee et al. (2000)
PQRPQRS PBMC-30a, TU Chatterjee et al. (2000)
PQOPQRS WL-1 Do¨rries et al. (1994)
Placenta PQS PQ Pietropaolo et al. (1998)
Prostate PQPQRS URO1 Monini et al. (1995)
Sewage PQRS SA160900,SA090600,RA;U2,U3,U5 Bofill-Mas et al. (2001)
Ureter PQPQRS URO1 Monini et al. (1995)
Urine PQ T5R.BK clone 4 Li et al. (2002)
PQR T1R1.BK Li et al. (2002)
PQRS Azzi-U;BMT Azzi et al., unpublished; Priftakis et al. (2001, 2003)
G7RBK, K8R2.BK, T4R3 Li et al., unpublished,
HC-u2,-u5,-u9, HI-u2,-u6,-u8; Chen et al. (2004)
MT-1,cl-6,-8,-50,-87,-93,-108 Sugimoto et al. (1989)
S1,S2,S3,P1 Bhattacharjee and Chakraborty, (2004)
Seq 1-5, 7-10 Takasaka et al. (2004)
TC-1,TC-2; Pat-A, Pat-E Tsai et al., Chang et al. (1996a, b); Scha¨tzl et al. (1994)
WW, WWT Rubinstein et al. (1987); Sundsfjord et al. (1990)
Fl&gstad et al. (1991); Markowitz et al. (1991)
Negrini et al. (1991); Sundsfjord et al. (1999);
Stoner et al. (2002); Jbrgensen et al. (2003)
PPPQS NP164(=proto-2) Sundsfjord et al. (1994a)
PQPQS T4R4.BK Li et al. (2002)
PPQRS BMT-14 , cl-51,-54,-59,-97; Seq 6 Negrini et al. (1991); Sugimoto et al. (1989);
Takasaka et al. (2004)
PQPQRS T2Rbkit2,T2R.1BK(=T2RBkit21-1) Li et al. (2002)
PQRQRS T2R.2BK Li et al. (2002)
POPPQRS cl-7,-47,-104,-111 Sugimoto et al. (1989)
PQROPQRS cl-9,-11,-18,-29,-32-34,-80,-120 Sugimoto et al. (1989)
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Table 3
Point mutations in the P, Q, R, and S blocks compaired to the consensus sequence as shown in Fig. 1
Position Mutation Strain Accession number References
Mutations P-block
P4-P5 insertion CA URO1 U33549 Monini et al. (1995)
P5 DG AO AF123403 Sundsfjord et al. (1999)
P14 TYC G7RBK AF374595 Li et al. (2002)
P17 DT AO AF123403 Sundsfjord et al. (1999)
P18 TYA WW M15987 Rubinstein et al. (1987)
WW(BMT-12,15,16,19) Negrini et al. (1991)
WW Jbrgensen et al. (2003)
T4R4.BK AF442905 Li et al. (2002)
TIM.BK AF442900 Li et al. (2002)
K8R2.BK clones 2,3 AF442897 + AF442896 Li et al. (2002)
SA160900 AF356533 Bofill-Mas et al. (2001)
SA090600 AF356532 Bofill-Mas et al. (2001)
RA AF356531 Bofill-Mas et al. (2001)
TYC WW Pat-A and Pat-E S72998 Scha¨tzl et al. (1994)
P19 DA BK-OV1 AY573928 Asomani et al., unpublished
P18—P19 insertion T WW Markowitz et al. (1991)
P24—P25 insertion G BK-OV1 AY573928 Asomani et al., unpublished
P24 TYC WW AF123397 Sundsfjord et al. (1999)
AF123410–AF123416 Sundsfjord et al. (1999)
TYA WW AF123399 Sundsfjord et al. (1999)
P27 AYG BKV(Cal) AF317623 Bhattacharjee and Chakraborty,
unpublished
S3 Bhattacharjee and Chakraborty, (2004)
P30 CYT BKV(Cal) AF317623 Bhattacharjee and Chakraborty,
unpublished
WW M15987 Rubinstein et al. (1987)
WW Jbrgensen et al. (2003)
T4R4.BK AF442905 Li et al. (2002)
T1R1.BK AF442901 Li et al. (2002)
TIM.BK AF442900 Li et al. (2002)
K8R2.BL clones 2 and 3 AF442896 + AF442897 Li et al. (2002)
SA160900 AF356533 Bofill-Mas et al. (2001)
SA090600 AF356532 Bofill-Mas et al. (2001)
RA AF356531 Bofill-Mas et al. (2001)
S1,S2,S3 Bhattacharjee and Chakraborty (2004)
P1 Bhattacharjee and Chakraborty (2004)
P31 CYT Seq 5, 6 Takasaka et al. (2004)
P33 GYA TC-1 Chang et al. (1996a, 1996b)
TC-2 Chang et al. (1996b)
AO AF123404 Sundsfjord et al. (1999)
P35 DC URO1 U33549 Monini et al. (1995)
P43 GYA PQ Pietropaolo et al. (1998)
P45 CYG T2R.2B AF442892 Li et al. (2002)
DC T5R.BK4 AF442906 Li et al. (2002)
T1R1.BK AF442901 Li et al. (2002)
P47 DT E00430 Soeda et al., unpublished
P49—P50 insertion T T5R.BK4 AF442906 Li et al. (2002)
P53 AYC BMT-7,14 Negrini et al. (1991)
AYG BMT-8,9,10,12,13,15,
16,17,18,19
Negrini et al. (1991)
P55 GYT P1 Bhattacharjee and Chakraborty (2004)
GYC Seq 4 Takasaka et al. (2004)
P56 AYG BKV(Cal) Bhattacharjee and Chakraborty,
unpublished
P1 Bhattacharjee and Chakraborty (2004)
DA BMT-7,14 Negrini et al. (1991)
P58 DA Seq 4 Takasaka et al. (2004)
P62 CYA AO AF123404 Sundsfjord et al. (1999)
P63 AYC AO AF123404 Sundsfjord et al. (1999)
P64 TYC T2R.2B AF442892 Li et al. (2002)
P66 AYT E00430 Soeda et al., unpublished
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Table 3 (continued )
Position Mutation Strain Accession number References
Mutations in Q-block
Q2—Q3 insertion T AO AF123404 Sundsfjord et al. (1999)
Q7 CYG WW Pat-E S72998 Scha¨tzl et al. (1994)
T5R.BK4 AF442906 Li et al. (2002)
WWT3 Fl&gstad et al. (1991)
Randhawa et al. (2003)
PQ Pietropaolo et al. (1998)
Shi 1-6 Agostini et al. (1995)
Q8 CYG WW Markowitz et al. (1991)
Randhawa et al. (2003)
Q15 TYA DDP U91605 Dolei et al. (2000)
PQ Pietropaolo et al. (1998)
Q18 CYT TC-2 Chang et al. (1996b)
Q21 TYG AO AF123404 Sundsfjord et al. (1999)
Q27 GYC TC-2 Chang et al. (1996b)
Q34 CYT Seq 10 Takasaka et al. (2004)
Q36 CYG BMT Priftakis et al. (2001, 2003)
Q38 CYG BMT Priftakis et al. (2001, 2003)
Q39 DC WW AF123398 Sundsfjord et al. (1999)
Mutations in R block
R2 CYG TC-2 Chang et al. (1996b)
CYA TC-3 Chen et al. (2001)
TU M34049 Sundsfjord et al. (1990)
MT-1 Sugimoto et al. (1989)
Seq 7, 8 Takasaka et al. (2004)
CYT BMT Priftakis et al. (2001, 2003)
R3—R4 insertion T AO AF123403 + AF123404 Sundsfjord et al. (1999)
R5 AYG WL-1 S67523 Do¨rries et al. (1994)
T3R2.BK AF442903 Li et al. (2002)
A191-2 AF218448 Chang et al., unpublished
V173-1 AF218445 Chang et al., unpublished
A250-1-a AF218447 Chang et al., unpublished
Seq 1, 3 Takasaka et al. (2004)
WW AF123401 + AF123402 +
AF123422–AF123428
Sundsfjord et al. (1999)
R6 AYG WW Markowitz et al. (1991)
BMT13 Negrini et al. (1991)
AYC BMT7 Negrini et al. (1991)
R7 AYT WW Markowitz et al. (1991)
R10 CYG WW AF123398 Sundsfjord et al., 1999
R
R12 CYT Seq 10 Takasaka et al. (2004)
R13 AYC BKV(CAL) AF317623 Battacharjee and Chakraborty, unpublished
S3 Battacharjee and Chakraborty, 2004
AYT Azzi-K AY272187 Azzi et al., unpublished
R17 AYT Azzi-U AY272186 Azzi et al., unpublished
R23 AYC BKV(CAL) AF317623 Battacharjee and Chakraborty, unpublished
S3 Bhattacharjee and Chakraborty (2004)
R24 AYC S1,S2,S3 Bhattacharjee and Chakraborty (2004)
R26 AYG T3R2.BK AF442903 Li et al. (2002)
R29 AYG HI-u6,CAP-m5, HI-u8 AY628237, AY628232, AY628238 Chen et al. (2004)
R35 AYG BKV(CAL) AF317623
S3 Bhattacharjee and Chakraborty (2004)
R38 CYG WL-1 S67523 Do¨rries et al. (1994)
BMT-13 Negrini et al. (1991)
WW Jbrgensen et al. (2003)
A191-2 AF218448 Chang et al., unpublished
V173-1 AF218445 Chang et al., unpublished
V128-1 AF218446 Chang et al., unpublished
WW AF123401 + AF123402 Sundsfjord et al. (1999)
WW AF123422–AF123427 Sundsfjord et al. (1999)
CYT A250-1-a AF218447 Chang et al., unpublished
(continued on next page
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Table 3 (continued )
Position Mutation Strain Accession number References
Mutations in R block
R39 TYC A191-2 AF218448 Chang et al., unpublished
V173-1 AF218445 Chang et al., unpublished
TYA A250-1-a AF218447 Chang et al., unpublished
R40 GYA WL-1 S67523 Do¨rries et al. (1994)
WW Jbrgensen et al. (2003)
A191-2 AF218448 Chang et al., unpublished
V173-1 AF218445 Chang et al., unpublished
V128-1 AF218446 Chang et al., unpublished
Seq 1 Takasaka et al. (2004)
WW AF123401 + AF123402 +
AF123422–AF123428
Sundsfjord et al. (1999)
GYT BMT2,7,8,9,10,12,15,
16,17,18,19,13
Negrini et al. (1991)
Seq 4 Takasaka et al. (2004)
R41 GYT Azzi-K, Azzi-U AY272186 + AY272187 Azzi et al., unpublished
Seq 4 Takasaka et al. (2004)
GYA BMT-13 Negrini et al. (1991)
DG A250-1-a AF218447 Chang et al., unpublished
R42 CYG BMT2,8,9,10,12,13,15-19 Negrini et al. (1991)
CYT BMT7 Negrini et al. (1991)
R43 CYA BKV(CAL) AF317623 Bhattacharjee and Chakraborty, unpublished
S3 Bhattacharjee and Chakraborty (2004)
R47 DG BKV(CAL) AF317623 Bhattacharjee and Chakraborty, unpublished
S3 Bhattacharjee and Chakraborty (2004)
R58 CYT TC-3 Chen et al. (2001)
TU Sundsfjord et al. (1990)
MT-1 Sugimoto et al. (1989)
Seq 5-10 Takasaka et al. (2004)
Mutations in S-block
S2 AYC WW Markowitz et al. (1991)
S10 GYA E00430 Soeda et al., unpublished
S22 TYG WL-1 S67523 Do¨rries et al. (1994)
WW Jbrgensen et al. (2003)
A191-2 AF218448 Chang et al., unpublished
A250-1-a AF218447 Chang et al., unpublished
V128-1 AF218446 Chang et al., unpublished
V173-1 AF218445 Chang et al., unpublished
WW AF123401; AF123402,
AF123422–AF123428
Sundsfjord et al. (1999)
MT-1 Sugimoto et al. (1989)
TYC BK-OV1 AY573928 Asomani et al., unpublished
S23 AYG TC-3 Chen et al. (2001)
Seq 7-10 Takasaka et al. (2004)
S24 GYA Azzi-K, Azzi-U AY272186 + AY272187 Azzi et al., unpublished
S29 CYG TC-3 Chen et al. (2001)
MT-1 Sugimoto et al. (1989)
Seq 7-10 Takasaka et al. (2004)
CYT DDP Degener et al. (1999); Dolei et al. (2000)
WWT1 Fl&gstad et al. (1991)
S44 AYC TIM.BK AF442900 Li et al. (2002)
S49-S50 insertion T WL-1 S67523 Do¨rries et al. (1994)
BK-OV1 AY573928 Asomani et al., unpublished
BKV(CNS) AY236489 Jbrgensen et al. (2003)
WW Jbrgensen et al. (2003)
Azzi-K,Azzi-U AY272186 + AY272187 Azzi et al., unpublished
A191-2 AF218448 Cheng et al., unpublished
A250-1-a AF218447 Cheng et al., unpublished
V128-1 AF218446 Cheng et al., unpublished
V173-1 AF218445 Cheng et al., unpublished
Seq 1, 2 Takasaka et al. (2004)
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Table 3 (continued )
Position Mutation Strain Accession number References
Mutations in S-block
WW AF123401, AF123402,
AF123422–AF123428
Sundsfjord et al. (1999)
S57 DA WL-1 S67523 Do¨rries et al. (1994)
S58 DA WL-1 S67523 Do¨rries et al. (1994)
S59 DA WL-1 S67523 Do¨rries et al. (1994)
S60 DG WL-1 S67523 Do¨rries et al. (1994)
S61 DG WL-1 S67523 Do¨rries et al. (1994)
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electropherogram. Therefore, sequences of BKV genomes
poorly presented in the biological samples may be over-
looked due to technical limitations of the PCR-based
sequencing methods. Less abundant DNA (e.g., rearranged
TCR) are more likely to be picked up by cloning if sufficient
colonies are analyzed. Another disadvantage with PCR that
faces researchers is the problem of contamination with
laboratory strains. The detection of BKV strains with TCRs
present in passaged laboratory strains should be interpreted
with care. Several distinct TCR variants were also obtained
after cloning BKV DNA from urine of a single patient with
systemic lupus erythematosus. In addition to archetypal
PQRS (referred to as MT-1 by the authors), rearranged
TCRs were found. Many of these TCR variants contained a
duplication of part of the O block, which spans the origin of
replication (Sugimoto et al., 1989). These findings are in
agreement with in vitro studies that have demonstrated that
serial passage of BKV at high multiplicities of infection
resulted in the accumulation of rearranged genomes with
often more than one replication origin (Hara et al., 1986;
Rubinstein et al., 1991; Sugimoto et al., 1989; Watanabe
and Yoshiike, 1986). The non-coding control region of
BKV WL-1 consists of an O-block and a transcriptional
control region with PQOPQRS anatomy. Up to date, BKV
WL-1 is the only other non-passaged strain described that
contains duplicated O block sequences in its non-coding
control region. This BKV strain was detected by PCR in
peripheral blood leukocytes from healthy adult individuals
(Do¨rries et al., 1994).
The results outlined above show that different TCR
variants circulate in different cell types of the same patient.
However, several cases have reported the presence of a
unique strain in different tissues of the same or distinct
patients. Azzi et al. found archetypal BKV with the PQRS
TCR in the kidney as well as in the urine of a renal allograft
transplant patient. The urine isolate had an unique mutation
of nucleotide 13 in the R block replacing an A by a T, while
in the kidney isolate T at R17 was mutated into A. Both
isolates had the mutations GYA at R41, GYA at S24, and
an insertion of T between S49 and S50 [Azzi et al., GenBank
accession nos. AY273186 and AY273187]. Identically
rearranged variants have been detected in PCR amplified
BKV DNA from neoplastic and nonneoplastic tissue from
different patients. The new variant URO1 (PQPQRSanatomy) was found in bladder, kidney, ovarium, prostate,
and ureter samples (Monini et al., 1995). Examining fetal
brain, kidney from different aborted fetuses and placenta
from different mothers revealed PCR-amplified BKV TCR
sequences with a PQS anatomy in all positive cases
(Pietropaolo et al., 1998). This PQ strain was later also
identified by different groups as the DDP strain in peripheral
blood cells of HIV-positive and -negative individuals and
healthy donors (Chatterjee et al., 2000; Degener et al., 1999;
Dolei et al., 2000). A PQ TCR variant with only P and Q
block sequences (T5R.BK isolate) was detected in the urine
of a renal transplant recipient (Li et al., 2002). In a recent
study, 15 full-length BKV genomes were generated by PCR,
cloned, and subsequently sequenced (Chen et al., 2004).
Nine clones were derived from the heart (4 clones) and
muscle (5 clones) tissue from a single renal transplant
recipient who developed BKV vasculopathy that led to
capillary leak syndrome (BKVCAP). Three clones each were
obtained from urine of a HIV-2-positive patient (BKVHI)
and from the urine of a healthy individual (BKVHC). All
clones had the archetypal PQRS control region, but one
BKVHI clone contained a 10 bp deletion in the P-block.
Only a few point mutations were detected between the
different clones (see Table 1). These results again illustrate
that different tissues from the same patient, and urine from
different patients contained similar BKV strains with respect
to their TCR.
In summary, the results from the above mentioned
studies suggest that analyzing the TCR cannot with
certainty predict cell tropism or strain-specific BKV-
associated disease. However, this conclusion may be
preliminary as only a limited number of different patients
and tissues were investigated. A larger number of tissues
and patients need to be deliberated. Moreover, if sufficient
material is available, cloning should be considered as PCR
preferentially allows the identification of the most prom-
inent species in a sample and renders the detection of
polymorphisms difficult.Polymorphism in the major capsid protein VP1
Despite nearly 35 years of intense BKV research, little
is known about the transmission, route of infection, host
cells, and mechanisms for spread of this virus. BKV, its
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detected in most human tissues and organs, including
bladder, blood, bone, bone marrow, brain, central nervous
system, CSF, cervix, connective tissue, endothelial cells,
eye, heart, kidney, lips, liver, lung, lymph nodes, naso-
pharynx, mesentery, penis, pituitary gland, placenta,
prostate, saliva, skin, small intestine, sperm, spleen,
stomach, tongue, tonsils, urethra, and vulvae [for a
complete overview, see Rekvig and Moens, 2002]. The
range of cell types permissive for BKV infection has been
linked to cell-specific transcription factors involved in the
expression of the viral genome. However, it is also
becoming apparent that the presence of specific receptors
contributes to the tropism of BKV. The primary receptor-
binding determinant on BKV is the major capsid protein
VP1, and has been mapped to amino acid residues 61–83.
This region also encompasses the epitopes responsible for
serotype differences between BKV isolates (Atwood, 2001;
Randhawa et al., 2002a). It is conceivable that changes in
the VP1 protein represent a strategy adapted by the virus
to evade the host immune system, as well as to increase
the affinity or to broaden the range for cellular receptors.
Studies with polyomaviruses support a role for VP1 in cell
tropism. The human polyomavirus JC has a narrow cell
tropism and JC virions were unable to infect HeLa cells.
However, viral expression was monitored in HeLa cells
transfected with naked JCV DNA (Schweighardt and
Atwood, 2001). These findings indicate that the lack of
permissivity in these cells was at the level of virus
adsorption/uptake. Another observation that underscores
the importance of VP1 in the viral life cycle comes from a
mouse polyomavirus VP1 mutant. Substitutions of residue
92 (corresponds to amino acid 82 in BKV VP1) reduced
the plaque size and affected the hemagglutination behavior
of the mutant virus (Freund et al., 1991). The cellular
receptors for BKV have not been fully identified, but seem
to be glycolipids containing ubiquitous a(2–3)-linked sialic
acid modifications (Atwood, 2001). Amino acid changes in
the VP1 protein could be responsible for conformational
differences that may lead to preferential entry in specific
cells. Sequence analysis of the VP1 region of BKV-
positive biopsies has suggested that the viral genome is
unstable and changes in nucleotide sequences occur as
patients are followed over time (Randhawa et al., 2002b).
On the contrary, VP1 sequence analysis of urinary BKV in
100 urine samples from 21 SLE patients and 75 pregnant
women collected over a one-year period were predom-
inantly stable (Bendiksen et al., 2000). The sites of
mutations and mutation rates in the VP1 protein are
represented in Fig. 2 and Table 4. It should be noted,
however, that the mutation rate of a specific residue was
defined as the number of mutations found at this position
divided by the total number of published sequences of this
residue. The actual mutation frequency in the human
population may differ because several studies have
reported new mutations without stating how many samplesor patients that possessed this particular mutation. The
most hydrophobic regions of VP1 are located in two small
regions, at residues 61–83 and 214–236. Regions 61–83
are highly predisposed for mutations. This region, referred
to as the BC-loop, forms the antigenic determinants of
BKV subtypes and mediates adsorption to the host cell (Jin
et al., 1993; Liddington et al., 1991). In addition, high
mutation frequencies are observed at residues Q117, D175,
V210, and L362. Other hydrophobic residues substitute the
hydrophobic residues 210 and 362, while Q117 is replaced
by a basic lysine. The substitution of D175 into E
conserves the negative charge at this position in the
protein. A few mutations have only been reported in BKV
strains isolated from a particular tissue, but the number of
individuals is far too low to draw any conclusions. For
example, a BKV variant with the unique T4A, R170W and
E330G mutations was isolated from the heart of a single
patient, but as no other VP1 sequences are available from
heart tissue from distinct patients, it is impossible to draw
conclusions (see Table 4). Experimental data that may
provide an indication of the biological significance of these
mutations are lacking.Polymorphism in the large T-antigen
Large T-antigen plays a pivotal role in the life cycle of
BKV because it stimulates viral DNA replication and
controls expression of both early and late genes (Moens
and Rekvig, 2001). Moreover, large T-antigen affects the
expression of a large number of cellular genes probably to
create an optimal molecular environment for the virus
(Moens et al., 1997). Large T-antigen DNA sequences have
been detected in a wide variety of tissues (Rekvig and
Moens, 2002), yet few studies have determined the
sequences of large T-antigen. The BKV Cin-strain identified
in an AIDS patient with end-stage renal disease possessed a
Q169L mutation in the DNA-binding domain of large T-
antigen. Studies with SV40 large T-antigen have suggested
that this mutation may stabilize the binding of large T-
antigen to DNA. Whether this mutation enhances BKV
DNA replication remains to be investigated (Smith et al.,
1998). Comparing the amino acid sequences of large T-
antigen of the 15 different complete BKV isolates by Chen
et al. (2004) revealed that all these 15 non-passaged BKV
isolates had the I127T and the S260N substitutions
compared to the cell-passaged BKV (Dunlop) strain.
Additional substitutions that were found include, E20G,
P28S, K37R, H42R, E63G, K133E, S142C, S182P, T267A,
K273R, F288L, F323C, I327T, N334D, T354S, K373R,
I430V, 471V, F475G, D504G, F584S, E603K, D629G, and
Q675E. The mutations P28S, S142C, and T354S were only
present in virus shed in the urine from a healthy individual,
while the substitution Q675E was exclusive for the clones
obtained from the urine sample of a HIV-2 positive patient.
All other mutations were detected in single clones. The
Fig. 2. Position and mutation rate of reported mutations in the VP1 protein of BKV. The numbers refer to the positions of the amino acid residues in the protein.
The mutation rate for each residue (in %) was calculated as the number mutations reported at this side divided over the total number of sequences provided for
this particular residue. The loops emanating from the h-sheet, as described in (Liddington et al., 1991), are indicated at the top of the diagram.
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correspond with the previously described mutations 20, 28,
131, 140, 180, and 265, respectively, in SV40. However, all
of these SV40 large T-antigen mutations transformed and
stimulated viral DNA synthesis with wild-type levels,
whereas the K131T or R, the S140L, and the S180F
mutants exhibited reduced transformation efficiency of Rat-
1 cells, but retained wild-type DNA replication activity
(Kalderon and Smith, 1984; Rutila et al., 1986). A K131M
substitution resulted in an SV40 virus with slightly delayed
growth properties in cell culture (Colledge et al., 1986).
The biological consequences of the naturally occurring
mutations in BKV large T-antigen have not been system-
atically explored, although they may be extrapolated from
studies with the corresponding SV40 large T-antigen
mutants because of the extensive homology between the
proteins of these two viruses. One group examined the
effect of mutating histidine residue 42 in the J domain of
BKV large T-antigen. This domain shows extensive
homology to the DnaJ family of molecular chaperone
proteins and is required for efficient viral replication,
specific interaction with heat shock protein hsc70, and
transformation. Large T-antigen H42Q mutant protein
retained the ability to bind members of the retinoblastoma
family, but was severely impaired in both induction of the
transcriptional activity of the E2F family of transcription
factors and serum-independent growth of cells. Hence,
substitutions of H42 may have an effect on cell prolifer-
ation as both the retinoblastoma proteins and the E2F
transcription factors are involved in controlling cell cycle
progression (Harris et al., 1998).Polymorphism in the agnoprotein
The late region of BKV encodes a small phosphoprotein
referred to as the agnoprotein (Rinaldo et al., 1998). Little is
known about the function of this protein. The agnoproteins
of BKV (66 amino acids), SV40 (62 amino acids), and JCV
(71 amino acids) are highly identical, especially in the N-
terminal 50 amino acid residues of the protein (41/50
identical for BKV-JCV and 36/50 identical for BKV-SV40).
Studies with SV40 and JCV have suggested regulatory roles
for their agnoproteins at the levels of viral transcription,
replication, capsid protein translation, and assembly (Rad-
hakrishnan et al., 2004). JCVagnoprotein was also shown to
dysregulate the cell cycle by altering the expression of
several cyclins and their associated kinases. The JCV
agnoprotein can interact with p53 and the N-terminal 36
residues of the agnoprotein seem sufficient for this
interaction (Darbinyan et al., 2002). Comparing this region
with the corresponding domain of the BKV agnoprotein
reveals only three substitutions (K9Q, S19T, and L29F),
suggesting that BKV agnoprotein also may bind p53.
Interestingly, the BKV agnoprotein was found to interact
with an unidentified approximately 50 kDa protein (Rinaldo
et al., 1998).
Few studies have addressed the expression of the
agnogene in human tissues. Agnoprotein was detected in
the kidney (tubular epithelial cells) and brain (ependyma
cells) of a 26-year-old AIDS patient who developed
menigoencephalitis, retinitis, and nephritis, but no sequence
data were provided in this study (Bratt et al., 1999). Partial
agnogene sequences were obtained from urine samples of an
Table 4
Amino acid substitutions and their mutation rates in the BKV VP1 protein
Residue Mutation rate (%) Specimen Reference (GenBank accession no)
4TYA 1/28 (3.6) heart Chen et al. (2004) (AAT47371)
19KYE 1/28 (3.6) muscle Chen et al. (2004) (AAT47401)
20EYD 1/28 (3.0) urine Sugimoto et al. (1990) (CAA40235)
30DK 1/34 (2.9) urine Jin et al. (1993) (CAA79595)
42VYL 7/35 (20.0) urine, kidney,
brain, CSF, lung
Chen et al. (2004) (AAT47347; AAT47353; AAT47359);
Sugimoto et al. (1990) (CAA40247); Touze´ et al. (2001);
Stoner et al. (2002); Kupper et al. (1993) (P72390)
47EYQ 3/34 (8.8) urine Chen et al. (2004) (AAT47419); Stoner et al. (2002);
Kupper et al. (1993) (P72390)
60DYN 1/35 (2.9) urine Touze´ et al. (2001)
61EYD 19/135 (14.1) sewage, urine Tavis et al. (1989) (P14996);Bofill-Mas et al. (2001) (AAL31866);
Jin et al. (1995); Clewley, unpublished (S29968);
Jin et al. (1993) (CAA79596); Kupper et al. (1993) (P72390)
61EYN 7/134 (5.2) urine Clewley, unpublished (S29965); CAA79595; Jin et al. (1995)
62NYD 8/132 (6.1) urine Clewley, unpublished (S29965); Jin et al. (1993) (CAA79595);
Jin et al. (1995)
65GYD 6/155 (3.9) kidney Randhawa et al., 2002b
66FYY 38/155 (24.5) urine, kidney, sewage Bofill-Mas et al. (2001) (AAL31866);
Clewey, unpublished (S29965; S29968); Kupper et al. (1993) (P72390);
Tavis et al. (1989) (P14996);
Jin et al. (1993) (CAA79595; CAA79596); Jin et al. (1995);
Randhawa et al., 2002b
66FYW 8/155 (5.2) kidney Baksh et al. (2001)
68LYQ 1/155 (0.6) urine Tavis et al. (1989) (P14996)
68LYR 8/155 (9.6) kidney Rhandawa et al., 2002b
69KYH 17/155 (11.0) urine Tavis et al. (1989) (P14996); Jin et al. (1995)
69KYR 29/155 (18.7) kidney Clewley, unpublished (S29965); Jin et al. (1993) (CAA79595);
Jin et al. (1995); Baksh et al. (2001); Rhandawa et al., 2002b
69KYN 2/155 (1.3) kidney Baksh et al. (2001); Rhandawa et al., 2002b
70LYP 8/155 (5.2) kidney Rhandawa et al., 2002b
71SYT 30/155 (19.4) sewage, urine, kidney Bofill-Mas et al. (2001) (AAL31866);
Clewley, unpublished (S29965; S29968);
Kupper et al. (1993) (P72390); Jin et al. (1993) (CAA79595; CAA79596);
Jin et al. (1995); Baksh et al. (2001); Rhandawa et al., 2002b
72AYP 1/155 (0.6) kidney Rhandawa et al., 2002b
72AYG 1/155 (0.6) kidney Rhandawa et al., 2002b
73EYQ 2/155 (1.3) urine, heart Chen et al. (2004) (AAT47425; AAT47431)
73EYK 3/155 (1.9) urine, kidney Sugimoto et al. (1990) (CAA40243;); Baksh et al. (2001);
Rhandawa et al., 2002b
73EYD 5/155 (3.2) kidney Rhandawa et al., 2002b
73EYA 1/155 (0.6) kidney Rhandawa et al., 2002b
74NYT 25/155 (16.1) urine, kidney Jin et al. (1993) (CAA79595); Jin et al. (1995); Baksh et al. (2001);
Clewley, unpublished (S29965); Rhandawa et al., 2002b
75DYA 48/155 (31.0) urine, kidney, sewage Bofill-Mas et al. (2001) (AAL31862); Tavis et al. (1989) (P14996);
Clewley, unpublished; Jin et al. (1995); (S29965; S29968);
Kupper et al. (1993) (P72390); Jin et al. (1993) (CAA79595; CAA79596);
Baksh et al. (2001); Rhandawa et al., 2002b
75DYN 3/155 (1.9) kidney Baksh et al. (2001); Rhandawa et al., 2002b
76FYV 2/155 (1.3) kidney Rhandawa et al., 2002b
76FYD 1/155 (0.6) kidney Rhandawa et al., 2002b
77SYE 22/155 (14.2) urine, kidney Tavis et al. (1989) (P14996); Clewley, unpublished (S29965);
Jin et al. (1993) (CAA79595); Jin et al. (1995); Baksh et al. (2001);
Rhandawa et al., 2002b
77SYD 14/155 (9.0) urine, kidney Clewley, unpublished (S29968); Kupper et al. (1993) (P72390);
Jin et al. (1993) (CAA79596); Jin et al. (1995); Baksh et al. (2001);
Rhandawa et al., 2002b
77SYR 1/155 (0.6) kidney Rhandawa et al., 2002b
77SYK 2/155 (1.3) urine Jin et al. (1995)
77SYN 1/155 (0.6) kidney Baksh et al. (2001)
77SYQ 1/155 (0.6) kidney Baksh et al. (2001)
80SYD 2/155 (1.3) kidney Rhandawa et al., 2002b
80SYN 2/155 (1.3) kidney Rhandawa et al., 2002b
80SYQ 1/155 (0.6) kidney Rhandawa et al., 2002b
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Table 4 (continued )
Residue Mutation rate (%) Specimen Reference (GenBank accession no)
82EYD 61/155 (39.4) urine, kidney, sewage Bofill-Mas et al. (2001) (AAL31866); Tavis et al. (1989) (P14996);
Clewley, unpublished (S29965; S29968); Kupper et al. (1993) (P72390);
Jin et al. (1993) (CAA79595; CAA79596); Jin et al. (1995);
Baksh et al. (2001); Rhandawa et al., 2002b
82EYK 2/155 (1.3) kidney Baksh et al. (2001); Rhandawa et al., 2002b
82EYG 2/155 (1.3) urine Jin et al. (1995)
83RYK 8/155 (5.2) urine, kidney Jin et al. (1993) (CAA79596); Jin et al. (1995);
Clewley unpublished (S29968); P72390; Baksh et al. (2001);
Rhandawa et al., 2002b
97PYI 3/77 (3.9) urine Jin et al. (1995)
117QYK 9/36 (25.0) urine Bendiksen et al. (2000) (AAG23641; AAG23642);
Tavis et al. (1989) (P14996); Kupper et al. (1993) (P72390);
Clewley, unpublished (S29965; S29968);
Jin et al. (1993) (CAA79595; CAA79596); Jin et al. (1995)
121IYT 1/33 (3.0) muscle Chen et al. (2004) (AAT47413)
127LYP 1/33 (3.0) muscle Chen et al. (2004) (AAT47395)
139HYN 4/34 (11.8) urine Tavis et al. (1989) (P14996); Jin et al. (1993) (CAA79596);
Clewley, unpublished (S299967)
139HYT 1/34 (2.9) kidney Kupper et al. (1993) (P72390)
145IYV 5/34 (14.7) urine Tavis et al. (1989) (P14996); Jin et al. (1993) (CAA79596);
Clewley, unpublished (S29968); Kupper et al. (1993) (P72390)
146QYR 1/34 (2.9) urine Chen et al. (2004) (AAT474419)
158DYE 6/34 (17.6) urine, kidney,
brain, CSF, lung
Seif et al. (1979) (NP_041397); Sugimoto et al. (1990)
(CAA40235; CAA40239; CAA402476); Stoner et al. (2002)
170RYW 1/33 (3.0) heart Chen et al. (2004) (AAT47431)
171TYS 1/33 (3.0) urine Seif et al. (1979) (NP_041397)
175DYE 9/33 (27.3) urine, kidney,
muscle, heart
Chen et al. (2004) (AAT47347; AAT47353; AAT47359; AAT47419;
AAT47425; AAT47431); Sugimoto et al. (1990) (CAA40247; CAA40235);
Touze´ et al. (2001)
175DYQ 4/32 (12.5) urine Tavis et al. (1989) (P14996); Jin et al. (1993) (CAA79596);
Clewley, unpublished (S29968)
175DYH 1/32 (3.1) sewage Bofill-Mas et al. (2000) (AAF24120)
185AYV 1/33 (3.0) sewage Bofill-Mas et al. (2000) (AAF24120)
210VYI 10/29 (34.5) urine Chen et al. (2004) (AAT47347; AAT47353; AAT47359);
Tavis et al. (1989) (P14996); Sugimoto et al. (1990) (CAA40247; CAA40235)
Jin et al. (1993) (CAA79596); Clewley, unpublished (S29968);
Touze´ et al. (2001)
219TYA 3/29 (10.3) urine Seif et al. (NP_041397); Sugimoto et al. (1990) (CAA24307);
Touze´ et al. (2001)
225FYY 4/28 (14.3) urine Tavis et al. (1989) (P14996); Jin et al. (1993) (CAA79596);
Clewley, unpublished (S29968)
225FYL 1/28 (3.6) urine Sugimoto et al. (1990) (CAA40235)
259SYG 1/27 (3.7) muscle Chen et al. (2004) (AAT47413)
289IYT 1/27 (3.7) muscle Chen et al. (2004) (AAT47413)
301PYL 1/28 (3.6) urine Sugimoto et al. (1990) (CAA24307)
304FYS 1/28 (3.6) muscle Chen et al. (2004) (AAT47413)
305LYS 1/28 (3.6) urine Chen et al. (2004) (AAT47419)
311NYT 1/28 (3.6) heart Chen et al. (2004) (AAT47389)
313RYG 1/28 (3.6) urine Chen et al. (2004) (AAT47347)
316RYK 4/28 (14.3) urine Tavis et al. (1989) (P14996); Jin et al. (1993) (CAA79596);
Clewley, unpublished (S29968)
330EYG 1/28 (3.6) heart Chen et al. (2004) (AAT47371)
340RYQ 6/28 (21.4) urine Tavis et al. (1989) (P14996); Jin et al. (1993) (CAA79594; CAA79596);
Clewley, unpublished (S29967; S29968)
340RYK 2/29 (6.9) urine Sugimoto et al. (1990) (CAA40235); Touze´ et al. (2001)
353KYR 7/28 (25.0) urine, muscle Tavis et al. (1989) (P14996); Jin et al. (1993) (CAA79594; CAA79596);
Clewley, unpublished (S29967; S29968); Chen et al. (2004) (AAT47365)
362LYV 10/28 (35.7) urine Chen et al. (2004) (AAT47347; AAT47353; AAT47359);
Jin et al. (1993) (CAA79594; CAA79596);
Tavis et al. (1989) (P14996); Sugimoto et al. (1990) (CAA40247);
Clewley, unpublished (S29967; S29968)
The VP1 sequence of BKV Dunlop was used as reference except for residues 153, 171, and 210 where D, T, and V, respectively were chosen as these are mos
common in other BKV strains. The mutation rate of a specific residue is calculated as the number of reported substitution over the total number of sequences
provided for this amino acid residue.
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patient (Pat-E). In the N-terminal 46 amino acids, sub-
stitutions V14L, E43K, and V46D were found in Pat-A,
while only the latter mutation was present in Pat-E when
compared with the agnoprotein sequence of BKV Dunlop
(Scha¨tzl et al., 1994). Full-length BKV agnosequences were
successfully amplified by PCR from kidney, urine, lung,
CSF, and brain of a patient with chronic lymphocytic
leukemia. Sequence analyses of the amplicons revealed no
mutations compared to the BKV (Dunlop) sequences
(Stoner et al., 2002). The agnoprotein of the BKV (Cal)
strain had two mutations compared to Dunlop: G42S and
K49E [GenBank accession no. AF317623; Bhattacharjee
and Chakraborty, unpublished]. In a recent study, the
sequences of 15 full-length BKV genomes were determined
in heart, muscle, and urine of different patient groups (Chen
et al., 2004). Comparing the Dunlop agnoprotein sequence
with those 15 non-passaged BKV isolates revealed that the
three clones obtained from urine of a healthy control had the
V14L mutation, while all the clones obtained from the HIV-
2-positive patient and from the patient with BKV-associated
capillary leak syndrome possessed the substitution of S15G.
The Q9H mutation was unique for a strain cloned from the
heart of the patient with BKV-associated capillary leak
syndrome (CAP-h5 clone). One clone from a urine speci-
men of the HIV-2-positive individual (clone HI-u6) con-
tained a deletion removing amino acid residues 9–12 (Chen
et al., 2004). The V14L mutation had previously been
reported in urinary specimens of renal transplant recipients
[GenBank accession nos. AF411593, AF442892,
AF442893, AF442895, and AF442903; Li et al., 2002],
while the substitution S15G was also present in the non-
passaged BKV strains MT-I and WW (Sugimoto et al.,
1990). Functional studies exploring the effect of the
mutations in the BKV agnoprotein on the life cycle of the
virus are lacking. The cell propagated AS strain, with an 8
amino acid insertion between residues 1 and 2, and the
S15G mutation has been successfully propagated in a
variety of cells, suggesting that mutations in the BKV
agnogene are tolerated (Tavis et al., 1989). Cell-culture
infection studies with SV40 agnogene deletion mutants or
RNA interference that inhibits the expression of JCV
agnoprotein resulted in reduced virus yield, indicating a
important, but not crucial role for this protein [reviewed in
Moens and Rekvig, 2001; Orba et al., 2004; Radhakrishnan
et al., 2004].
The agnoprotein of BKV is a phosphoprotein with
putative phosphorylation sites Ser-7, Ser-11, Thr-21, and
Ser-64 for protein kinases like PKA, PKC, calmodulin
kinase-II, casein kinases-I and -II, and glycogen synthase
kinase-3. The phosphorylation and biological consequen-
ces of these putative phosphoacceptor sites have not
been confirmed, but it can be assumed that phosphor-
ylation/dephosphorylation events may affect the activity
of the agnoprotein. The fact that Ser-7 and Ser-11 are
conserved among BKV, JCV and SV40, while Thr-21 isconserved between BKV and JCV, and that no mutations
have been reported in these sites so far, strengthens this
assumption.Future perspectives
BKV is increasingly being recognized as an important
human pathogen, and has been associated with a wide
variety of renal, pulmonary, ophthalmologic, hepatic, auto-
immune, and even neurological diseases (reviewed in
Reploeg et al., 2001). It has been suggested that mutant
BKV strains with greater propensity for replication are
circulating in clinical populations and that BKV-associated
diseases could be linked to particular viral variants (Stoner
and Hu¨bner, 2001). Detailed sequence information may
therefore provide valuable information on the virulent
potencies of the different BKV strains. The development
of highly sensitive PCR techniques has led to the
identification of novel rearranged TCR and mutations in
viral proteins such as large T-antigen, VP1, and agnoprotein.
To date, sequence information of complete viral genomes of
non-passaged BKV is, however, scanty. This urges to
systematically examine the complete genome of non-
passaged strain directly obtained from a large diversity of
different tissues obtained from patients with a variety of
clinical conditions. A complete genomic identification of
BKV isolates may allow us to obtain a more profound
picture of genotypes associated with the pathophysiology of
this virus. Aimed experiments to address whether a novel
strain is more virulent in humans are hampered due to
obvious reasons. However, appropriate human cell cultures
or animal models may be used as alternatives, and may
provide some indications, but will never approach the real in
vivo situation.
Expanding our knowledge of the BKV genome poly-
morphism and understanding the adaptation of the virus
genome to its host may provide helpful information when
designing specific drugs that prevent or quench viral
reactivation and spread of the virus. Some feasible
strategies, which require a detailed knowledge of the BKV
genomes could include:
(1) The design of specific antibodies or inhibitors that
prevent viral adsorption. This requires a fine mapping
of the VP1 amino acids crucial for host cell receptor
interaction.
(2) The development of specific inhibitors for large T-
antigen that can prevent viral replication or/and viral
gene expression.
(3) The use of small interfering RNA technique. Viral
protein expression and virus production were success-
fully blocked in cell cultures transiently transfected
with siRNA against JCV large T-antigen and agno-
protein (Orba et al., 2004; Radhakrishnan et al.,
2004). Although it was proven that siRNA against
U. Moens, M. Van Ghelue / Virology 331 (2005) 209–231 229the JCV agnogene was very effective, it was also very
specific. The siRNA directed against JCV agnogene
differed only in two nucleotides from the BKV
agnogene, yet it was completely unable to inhibit
BKV agnoprotein expression. This exemplifies that a
detailed knowledge of the circulating BKV genomes
in the human population is necessary because genome
diversity may lead to the unwanted design of
ineffective siRNA molecules. The proven specificity
and efficiency of the siRNA technique in cell culture
should encourage its clinical applications in patients.
SiRNA delivery in patients may be facilitated by the
findings that recombinant polyomavirus VP1 is able to
self-assemble into virus-like particles and deliver
plasmid DNA into cells (Kimchi-Sarfaty et al., 2003;
Ou et al., 1999; Touze´ et al., 2001). In vitro packaging
of siRNA-encoding plasmids using VP1 should there-
fore be considered in gene transfer trials. Detailed
knowledge of the VP1 epitopes and receptor binding
sites may circumvent unwanted host immune
responses and increase the uptake by target cells
when applying BKV-like particles as a gene transfer
vector in patients.
(4) Immunization with attenuated strains could also be
considered and has been successfully applied for
animal polyomavirus (Ritchie et al., 1998).
The application of specific and efficient anti-viral
therapeutics could prevent exacerbation of the course of
the disease and improve the condition of patients suffering
from an active BKV infection.Acknowledgments
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